SciELO - Scientific Electronic Library Online

vol.22 número3Adherencia a quimioprofilaxis de niños chilenos expuestos a tuberculosis del adulto índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Revista chilena de enfermedades respiratorias

versión On-line ISSN 0717-7348


MANRIQUEZ, Jorge et al. Spirometric reversibility in COPD patients: 200 or 400 mg salbutamol should be used? . Rev. chil. enferm. respir. [online]. 2006, vol.22, n.3, pp.168-175. ISSN 0717-7348.

The optimal dose of salbutamol for testing spirometric reversibility in patients with chronic obstructive pulmonary disease (COPD) has not been determined and either 200 or 400 µg are commonly used. The purpose of the present study is to test both doses in a group of patients with mild to severe COPD. Forty stable COPD patients were included to receive in random order both doses of salbutamol, with spirometry being performed before and after 15 min of their administration. Absolute and percent predicted changes were evaluated. For the latter, an increase in forced expiratory volume in one second (FEV1), slow vital capacity (SVC), forced vital capacity (FVC) and inspiratory capacity (IC) equal or greater than 10% predicted was considered clinically significant. No differences were found in absolute post-bronchodilator values between the two doses. In addition, the proportion of responders to 200 and 400 µg of salbutamol according to the percent predicted changes was similar with both doses. This was particularly true when all variables related to volume changes (SVC, FVC, and IC) were included in the analysis. In conclusion, the present results indicate that for testing spirometric reversibility in COPD patients the 200 µg dose of salbutamol is as effective as the 400 µg dose

Palabras clave : spirometry; reversibility; albuterol; COPD.

        · resumen en Español     · texto en Español


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons